fda bpc-157 compounding category 2 list Approval Status 2026: Clinical Trials BREAKING: The FDA just reversed

BREAKING: The FDA just reversed theIR 2023 peptide ban. 12 peptides were just pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu (injectable) FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA's Overreach on Compounded Peptides BPC 157 just got voted in favor to be added to the 503A Bulk Drug Substances list, meaning a huge step towards being able to be prescribed and compounded in the US. Thank FDA Panel to Review 7 Peptides in July (2026)

SKU: 32973644443 · From metron-ms.com